This company has been marked as potentially delisted and may not be actively trading. ContraVir Pharmaceuticals (CTRV) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CTRV vs. ORGS, VRPX, SCPS, VAXX, EVLO, CMRA, ARDS, STAB, AMPE, and PXMDShould you be buying ContraVir Pharmaceuticals stock or one of its competitors? The main competitors of ContraVir Pharmaceuticals include Orgenesis (ORGS), Virpax Pharmaceuticals (VRPX), Scopus BioPharma (SCPS), Vaxxinity (VAXX), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), and PaxMedica (PXMD). These companies are all part of the "medical" sector. ContraVir Pharmaceuticals vs. Its Competitors Orgenesis Virpax Pharmaceuticals Scopus BioPharma Vaxxinity Evelo Biosciences Comera Life Sciences Aridis Pharmaceuticals Statera Biopharma Ampio Pharmaceuticals PaxMedica Orgenesis (NASDAQ:ORGS) and ContraVir Pharmaceuticals (NASDAQ:CTRV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations. Do institutionals & insiders believe in ORGS or CTRV? 22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 1.1% of ContraVir Pharmaceuticals shares are owned by institutional investors. 5.7% of Orgenesis shares are owned by company insiders. Comparatively, 1.6% of ContraVir Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media refer more to ORGS or CTRV? In the previous week, Orgenesis' average media sentiment score of 0.00 equaled ContraVir Pharmaceuticals'average media sentiment score. Company Overall Sentiment Orgenesis Neutral ContraVir Pharmaceuticals Neutral Which has better valuation and earnings, ORGS or CTRV? ContraVir Pharmaceuticals has lower revenue, but higher earnings than Orgenesis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrgenesis$662K0.16-$55.36MN/AN/AContraVir PharmaceuticalsN/AN/A-$9.45MN/AN/A Is ORGS or CTRV more profitable? ContraVir Pharmaceuticals has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat ContraVir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Orgenesis-3,827.81% N/A -130.18% ContraVir Pharmaceuticals N/A -4,810.77%-130.14% Which has more volatility & risk, ORGS or CTRV? Orgenesis has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. Comparatively, ContraVir Pharmaceuticals has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. SummaryOrgenesis and ContraVir Pharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks. Get ContraVir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTRV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTRV vs. The Competition Export to ExcelMetricContraVir PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$34K$816.03M$5.54B$9.82BDividend YieldN/A4.84%4.62%4.12%P/E RatioN/A1.2030.0926.02Price / SalesN/A36.57461.38112.87Price / CashN/A19.5637.7558.93Price / BookN/A6.588.506.06Net Income-$9.45M-$4.11M$3.26B$265.11M ContraVir Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTRVContraVir PharmaceuticalsN/AN/AN/A-92.9%$34KN/A0.0014Gap DownORGSOrgenesis1.1665 of 5 stars$0.02flatN/AN/A$106K$662K0.00150VRPXVirpax PharmaceuticalsN/A$0.01flatN/A-99.9%$14KN/A0.007SCPSScopus BioPharmaN/A$0.00flatN/A+50.0%$13KN/A0.009VAXXVaxxinityN/A$0.00-99.7%N/A+110.0%$13KN/A0.0090Gap DownEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120CMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002ARDSAridis PharmaceuticalsN/A$0.00flatN/AN/A$5KN/A0.0030STABStatera BiopharmaN/A$0.00flatN/A-83.3%$5KN/A0.0020AMPEAmpio PharmaceuticalsN/A$0.00flatN/A+31.8%$3KN/A0.0020PXMDPaxMedicaN/A$0.00+100.0%N/AN/A$2KN/A0.002Gap Up Related Companies and Tools Related Companies Orgenesis Competitors Virpax Pharmaceuticals Competitors Scopus BioPharma Competitors Vaxxinity Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Aridis Pharmaceuticals Competitors Statera Biopharma Competitors Ampio Pharmaceuticals Competitors PaxMedica Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTRV) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredGet This Stock NowThis company is the lifeblood of AI data centers, yet almost no one has caught up with the story. Their hardwa...InvestorPlace | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ContraVir Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share ContraVir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access